MYRIAD GENETICS INC
MYGN · XNASCIK 899923fmd_0MP6QC3QT4ECMZJ6WDRDNAX0EPManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jul 01, 2008 to Sep 30, 2026, 70 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 729 | 744 | 851 | – | 557 | 691 | 678 | 753 | 838 | 825 |
| Cost of revenue | 145 | – | – | – | – | – | 202 | 236 | 252 | 248 |
| Gross profit | 584 | – | – | – | – | – | 476 | 517 | 585 | 577 |
| Research and development | 74 | 71 | 86 | – | 73 | 82 | 85 | 89 | 113 | 107 |
| Selling, general and administrative | 440 | 435 | 556 | – | 497 | 538 | 515 | 573 | 560 | 538 |
| Total operating expenses | – | – | – | – | – | – | 617 | 774 | 709 | 964 |
| Operating income | 44 | 122 | 8 | – | (290) | (191) | (141) | (257) | (124) | (387) |
| Interest expense | 6 | 3 | 12 | – | 11 | 7 | 3 | 3 | 3 | 11 |
| Interest and investment income | 1 | 2 | 3 | – | 2 | 1 | 3 | 3 | 2 | 2 |
| Other non-operating income (expense) | (8) | (2) | (8) | – | 6 | 133 | 0 | (5) | 0 | (8) |
| Income before taxes | 36 | 120 | 0 | (223) | – | (57) | (141) | (262) | (124) | (395) |
| Income tax expense | 19 | (13) | (4) | – | (60) | (30) | (29) | 1 | 4 | (29) |
| Net income from continuing operations | 17 | 133 | 4 | (163) | – | (27) | (112) | (263) | (127) | (366) |
| Net income | 17 | 133 | 5 | – | (224) | (27) | (112) | (263) | (127) | (366) |